Mounjaro® (tirzepatide) is one of the most clinically effective weight loss treatments available today, delivering greater average weight loss than semaglutide (Wegovy®), including in patients with and without type 2 diabetes.
Results from Clinical Studies:
- Average weight loss of up to 22.5% of body weight over 72 weeks (SURMOUNT-1 trial).
- In comparison, the STEP 1 trial showed average weight loss of around 15% with semaglutide (Wegovy®) over a similar period.
These results make Mounjaro® one of the most powerful GLP-1-based treatments currently available for weight loss.